$84,091,682
SHINE WAS FOUNDED IN 2010 WITH THE GOAL OF BECOMING THE WORLD LEADER IN THE SAFE, CLEAN, AFFORDABLE PRODUCTION OF MEDICAL ISOTOPES. SINCE 2010, SHINE HAS AGGRESSIVELY PURSUED THE ESTABLISHMENT OF A DOMESTIC SOURCE OF HIGH SPECIFIC ACTIVITY MO-99 WITHOUT THE USE OF HEU TO END THE CHRONIC SHORTAGES US PATIENTS ARE EXPERIENCING.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Latest obligation on the 2021 SHINE contract to advance domestic production of molybdenum-99 medical isotopes without enriched uranium.
Ending U.S. dependence on foreign medical isotope supplies reduces chronic shortages affecting millions of patients needing diagnostic and therapeutic nuclear medicine.
Domestic Mo-99 production eliminates reliance on foreign suppliers and reduces supply-chain vulnerability for hospitals and imaging centers nationwide.
Securing domestic medical isotope production reduces geopolitical leverage of foreign suppliers and strengthens U.S. healthcare independence.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-31. Cost: $0.003012.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier ASST_NON_DENA0004010_089.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.